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Red Blood Cell Distribution Width Can Predict  
Vasculitis Activity and Poor Prognosis in  
Granulomatosis with Polyangiitis
Ho Jae Kim1, Juyoung Yoo1, Seung Min Jung1, Jason Jungsik Song1, Yong-Beom Park1, and Sang-Won Lee1,2
1Division of Rheumatology, Department of Internal Medicine and 2Institute for Immunology and Immunological Diseases,  
Yonsei University College of Medicine, Seoul, Korea. 
Purpose: We investigated whether red blood cell distribution width (RDW) predicts vasculitis activity based on Birmingham vas-
culitis activity score (BVAS) or BVAS for granulomatosis with polyangiitis (GPA) at diagnosis and poor prognosis during follow-up 
in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). 
Materials and Methods: We reviewed the medical records of 150 patients with AAV. We defined severe GPA as BVAS for GPA ≥7 
(the highest quartile). Correlation and standardised correlation coefficients were analysed by linear regression tests. The differences 
between groups were evaluated by Mann-Whitney test. Relative risk (RR) was assessed by chi square test and Cox hazards model. 
Results: RDW was correlated only with the vasculitis activity of GPA among patients with AAV. An increase in RDW was associat-
ed with the absence of ear nose throat (ENT) manifestation, but not proteinase 3-ANCA. Significant differences were noted in cu-
mulative refractory free survival according to RDW ≥15.4% (p=0.007) and the absence of ENT manifestation (p=0.036). Multivari-
ate Cox hazards analysis identified RDW ≥15.4% as the only significant predictor of refractory disease in GPA (RR 17.573).
Conclusion: RDW predicts vasculitis activity in GPA, and RDW ≥15.4% at diagnosis may increase the risk of severe GPA at diagno-
sis and predict refractory diseases during follow-up. 
Key Words: Red blood cell distribution width, ANCA-associated vasculitis, granulomatosis with polyangiitis, vasculitis activity 
score, prognosis 
INTRODUCTION
The 2012 revised International Chapel Hill Consensus Confer-
ence (CHCC) classifies systemic vasculitis affecting small ves-
sels into two groups, immune complex small vessel vasculitis 
and antineutrophil cytoplasmic antibody (ANCA)-associated 
vasculitis (AAV). AAV is also categorised into three variants 
comprising microscopic polyangiitis (MPA), granulomatosis 
with polyangiitis (GPA, also called Wegener’s granulomatosis), 
and eosinophilic GPA (EGPA, also called Churg-Strauss syn-
drome).1 Since MPA is not reflected in the classification crite-
ria proposed by the American College Rheumatology (ACR),2 
MPA is currently classified by 2012 CHCC and the 2007 Euro-
pean Medicines Agency (EMA) classification,3 which includes 
1) no fulfilment of the ACR classification criteria for GPA or 
EGPA,4,5 2) clinical and histologic features compatible with 
small vessels vasculitis, 3) no GPA surrogate markers, 4) my-
eloperoxidase (MPO)-ANCA or proteinase 3 (PR3)-ANCA posi-
tivity, and 5) renal limited vasculitis. 
In contrast to MPA, GPA and EGPA can be classified by the 
ACR classification criteria.4,5 GPA commonly affects respiratory 
tracts and kidneys, while EGPA is characterized by allergic fea-
tures such as asthma and eosinophilia. The methods to evalu-
ate the vasculitis activity of AAV includes Birmingham vascu-
litis activity score (BVAS),6 BVAS for GPA,7 disease extent index,8 
and five factor score [FFS (1996) and FFS (2009)].9,10 Among 
them, BVAS or BVAS for GPA is the most widely used to assess 
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the vasculitis activity of AAV. 
Red blood cell (RBC) distribution width (RDW) is a routinely 
measured value of heterogeneity in the size of circulating RBCs. 
RDW is calculated from the coefficient of variation of RBC vol-
ume distribution as follows: RDW=standard deviation of RBC 
volume distribution/mean corpuscular volume (MCV) ×100. 
RDW is clinically used to differentiate between different types 
of anaemia.11 When RDW is elevated, low MCV suggests iron 
deficiency, while high MCV implies folate or vitamin B12 defi-
ciency and immune haemolytic anaemia. When RDW in nor-
mal, normal MCV favours chronic disease, while high MCV 
represents aplastic anaemia.11 Meanwhile, RDW has been con-
sidered to be associated with disease activity or prognosis of 
various inflammatory diseases including rheumatic diseases.12-15 
To our best knowledge, there have been no reports regarding 
RDW in patients with AAV to date. Hence, in this study, we in-
vestigated whether RDW could predict not only vasculitis ac-
tivity based on BVAS or BVAS for GPA at diagnosis, but also poor 
prognosis during follow-up in 150 patients with AAV.
MATERIALS AND METHODS
Patients
We retrospectively reviewed the electronic medical records of 
150 patients with AAV registered in the Severance Hospital Au-
toimmune Vasculitides cohort according to the following in-
clusion criteria:16-19 1) patients who had been initially diagnosed 
with MPA, GPA, or EGPA from October 2000 to January 2017 
at the Division of Rheumatology, Department of Internal Medi-
cine, Yonsei University College of Medicine, Severance Hospi-
tal; 2) patients who had been follow-up for more than 12 weeks 
after the first diagnosis of AAV in our institute; 3) patients who 
had fulfilled the 2012 revised CHCC or the 2007 EMA algo-
rithm for MPA1,3 and who had met the ACR 1990 criteria for 
the classification for GPA and EGPA;4,5 4) patients who had the 
initial results of MPO-ANCA or PR3-ANCA, but not ANCAs by 
immunofluorescence assay [IFA, perinuclear (P)-ANCA and 
cytoplasmic (C)-ANCA], and those who did not have both AN-
CAs; 5) patients who had not been accompanied by any med-
ical conditions that would influence the positivity of MPO-
ANCA or PR3-ANCA or RDW;11,20,21 6) patients who had never 
received medications for medical conditions mentioned above 
upon searching by the Korean Drug Utilization Review (DUR) 
system at diagnosis; and 7) patients whose medical records 
contained accurate descriptions enough to calculate BVAS or 
BVAS for GPA and FFS (1996) and FFS (2009) on the same day 
of blood collection for laboratory tests at diagnosis.6,7,9,10 This 
study was approved by the Institutional Review Board of Sev-
erance Hospital (IRB no. 4-2017-0673).
Clinical and laboratory information 
We collected age, gender, and the follow-up duration as demo-
graphic variables, and the follow-up duration was defined as 
the period from diagnosis to the date of the current study. Over-
all clinical items were similar between BVAS and BVAS for 
GPA, although detailed differed. Thus, we obtained organ-
based clinical information, such as general, cutaneous, mucous 
membrane and eye, ear nose throat (ENT), cardiovascular, gas-
trointestinal, pulmonary, renal, and nervous systemic mani-
festations.6,7 Laboratory data included white blood cell, hae-
moglobin, RDW, prothrombin time (international normalised 
ratio), fasting glucose, blood urea nitrogen, creatinine, protein, 
serum albumin, alkaline phosphatase, aspartate aminotrans-
ferase, alanine aminotransferase, total cholesterol, erythro-
cyte sedimentation rate (ESR), and C-reactive protein (CRP). 
Vasculitis activity and definition of severe GPA and 
disease course 
The vasculitis activity of MPA and EGPA was assessed using 
BVAS and that of GPA was done using BVAS for GPA.6,7 Also, 
we searched clinical and laboratory features belonging to items 
of FFS (1996), as well as FFS (2009).9,10 In this study, the highest 
quartile of BVAS for GPA was 7 or greater, and we defined se-
vere GPA as BVAS for GPA ≥7. We previously reported that 
BVAS ≥9.5 at diagnosis is associated with refractory disease in 
Korean patients with GPA.17 However, because we focused on 
the potential of RDW to reflect cross-sectional activity of GPA, 
rather than predict refractory disease of GPA, we set the cut-
off of BVAS for severe disease at 7, the highest quartile of BVAS 
for GPA. Remission was defined as absence of disease activity 
attributable to active disease qualified by the need for on-go-
ing stable maintenance immunosuppressive therapy. Relapse 
was defined as recurrence or new onset of disease attributable 
to active vasculitis. Refractory disease was defined as unchanged 
or increased disease activity in acute vasculitis after 4 weeks of 
treatment with standard therapy or lack of response or chronic 
and persistent disease after over 12 weeks of treatment.22 
ANCA measurement 
MPO-ANCA and PR3-ANCA were measured by ELISA kits for 
anti-PR3 and anti-MPO (Inova Diagnostics, San Diego, CA, 
USA) before 2013, and by the novel anchor coated highly sen-
sitive Phadia ELiA (Thermo Fisher Scientific/Phadia, Freiburg, 
Germany) using human native antigens, performed on a Phad-
ia250 analyser after 2013. 
Statistical analysis 
Continuous variables are expressed as means±standard devi-
ations, and categorical variables are reported as numbers (per-
centages). Correlations between RDW and other continuous 
variables were analysed by univariate Pearson’s correlation 
analysis. Standardised correlation coefficients between BVAS 
for GPA and other continuous variables were assessed by mul-
tivariate linear regression analysis using variables with signifi-
cant differences in univariate analysis. The optimal cut-off of 
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RDW was extrapolated via calculating the area under the re-
ceiver operator characteristic curve (AUROC) and selected 
when the sum of sensitivity and specificity was maximised. In 
addition, relative risk (RR) of RDW under the initial BVAS for 
GPA ≥7 was evaluated using contingency tables and the chi 
square test. Significant differences in RDW between the pres-
ence and the absence of clinical manifestations and ANCA 
types were evaluated by the Mann-Whitney test. Due to the 
small number of subjects, we also applied univariate and mul-
tivariate Cox hazards models using variables with statistical 
significance to appropriately obtain RR. Kaplan-Meier surviv-
al analysis was used to analyse cumulative refractory disease 
free survival rate. All statistical analyses were conducted using 
SPSS software (version 23 for windows; IBM Corp., Armonk, 
NY, USA). p-values less than 0.05 were considered statistically 
significant.
RESULTS
Baseline characteristics of 150 patients with AAV
The baseline characteristics are described in Table 1. The 
mean age of the 150 patients [47 men (31.3%)] was 58.8 years 
old, and the mean follow-up duration was 49.8 months. Eighty-
seven patients (58.0%) were classified as MPA, 32 (21.3%) as 
GPA, and 31 (20.7%) as EGPA. Renal manifestation (56.0%) 
was the most frequently observed manifestation at diagnosis, 
followed by pulmonary manifestation (50.7%), general mani-
festation (46.0%), and ENT manifestation (38.7%). The mean 
BVAS or BVAS for GPA was 12.6, and the mean FFS (1996) and 
FFS (2009) were 0.7 and 1.6, respectively. Ninety-five patients 
(63.3%) had achieved remission without relapse, while 49 pa-
tients (32.7%) had ever experienced relapse after remission. 
Also 6 patients (4.0%) with GPA had never achieved remission 
during the disease course. MPO-ANCA was detected in 104 
patients (69.3%) and PR3-ANCA was found in 26 patients 
(17.3%). Twenty patients had neither MPO-ANCA nor PR3-
ANCA. The mean RDW was 14.3%, and the mean ESR and CRP 
values were 57.8 mm/hr and 29.0 mg/L, respectively. 
Correlation between RDW and other variables in all 
patients with AAV at diagnosis
Overall, RDW was not correlated with BVAS or BVAS for GPA 
in all AAV patients. However, when we categorised them into 
each variant of AAV, RDW was significantly correlated with 
BVAS for GPA in only GPA patients (r=0.461, p=0.008). Among 
other laboratory results, RDW was negatively correlated with 
protein (r=-0.261, p=0.001) and serum albumin (r=-0.183, p= 
0.025) levels, while it was positively correlated with blood urea 
nitrogen (r=0.166, p=0.042). RDW tended to be correlated 
with haemoglobin, but was not significant. There was no sig-
nificant correlation between RDW and ESR or CRP (Table 2).
Table 1. Baseline Characteristics of Patients with ANCA-associated 
Vasculitis (n=150)
Variables Values
Demographic data 
Age at diagnosis (yr) 58.8±16.1
Male gender, n (%)   47 (31.3)
Follow-up duration (yr)   49.8±46.4
Diagnosis, n (%)
Microscopic polyangiitis   87 (58.0)
Granulomatosis with polyangiitis   32 (21.3)
Eosinophilic granulomatosis with polyangiitis   31 (20.7)
Clinical manifestations at diagnosis, n (%)
General manifestations   69 (46.0)
Cutaneous manifestations   43 (28.7)
Mucous membranes/eyes manifestations 14 (9.3)
Ear nose throat manifestations   58 (38.7)
Cardiovascular manifestations   36 (24.0)
Gastrointestinal manifestations   9 (6.0)
Pulmonary manifestations   76 (50.7)
Renal manifestations   84 (56.0)
Nervous systemic manifestations   48 (32.0)
BVAS, BVAS for GPA and FFS at diagnosis
BVAS or BVAS for GPA 12.6±7.6
FFS (1996)   0.7±0.9
FFS (2009)   1.6±0.9
Disease course, n (%)
Remission and no relapse   95 (63.3)
Relapse after remission   49 (32.7)
Refractory disease (all GPA patients)   6 (4.0)
ANCA type at diagnosis, n (%)
MPO-ANCA 104 (69.3)
PR3-ANCA   26 (17.3)
ANCA negative   20 (13.3)
RDW at diagnosis (%) 14.3±2.4
Laboratory results at diagnosis
White blood cell (/mm3) 10190.1±4815.7
Haemoglobin (g/dL) 11.7±2.1
Platelet (×103/mm3)   317.0±132.6
Prothrombin time (INR) (n=116)   1.0±0.2
Fasting glucose (mg/dL) 115.1±42.2
Blood urea nitrogen (mg/dL)   24.5±24.1
Creatinine (mg/dL)   1.7±1.9
Protein (g/dL)   6.8±1.0
Serum albumin (g/dL)   3.6±0.8
Alkaline phosphatase (IU/L)   90.6±82.8
Aspartate aminotransferase (IU/L)   24.7±25.7
Alanine aminotransferase (IU/L)   22.4±28.2
Total cholesterol (mg/dL) 167.2±45.3
Acute reactants at diagnosis
ESR (mm/hr)   57.8±37.4
CRP (mg/L)   29.0±51.8
ANCA, antineutrophil cytoplasmic antibody; BVAS, Birmingham vasculitis ac-
tivity score; FFS, five factor scores; MPO, myeloperoxidase; PR3, proteinase 3; 
RDW, red blood cell distribution width; INR, international normalised ratio; 
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein. 
Values are expressed as a mean±standard deviation or n (%). 
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Correlation between RDW and other variables in 
patients with GPA at diagnosis
In GPA patients, RDW was significantly correlated with BVAS 
for GPA (r=0.461, p=0.008), and furthermore, it showed mean-
ingful correlations with FFS (1996) (r=0.455, p=0.009) and FFS 
(2009) (r=0.553, p=0.001). Among other laboratory results, 
RDW was negatively correlated with protein (r=-0.389, p= 
0.028), but not with haemoglobin. Similar to all patients with 
AAV, GPA patients exhibited no remarkable correlation be-
tween RDW and ESR or CRP (Table 3).
Univariate and multivariate linear regression analyses 
of BVAS for GPA and other variables in patients with 
GPA at diagnosis
Univariate linear regression analysis showed that BVAS for 
GPA was significantly correlated with RDW (r=0.461, p=0.008), 
and inversely correlated with creatinine (r=0.349, p=0.049). 
BVAS for GPA was also positively correlated with FFS (1996) 
(r=0.734, p<0.001) and FFS (2009) (r=0.354, p=0.047). Because 
FFS (1996) and FFS (2009) items partly overlap with BVAS for 
GPA items, we did not include FFS (1996) and FFS (2009) in 
multivariate linear regression analysis. Multivariate linear re-
gression analysis determined that RDW was the only inde-
pendent predictor of BVAS for GPA [β=0.393, 95% confidence 
interval (CI) 0.041–0.584, p=0.025] (Table 4). 
Comparison of RDW between the presence and 
absence of each clinical aspect and ANCA types in 
patients with GPA at diagnosis
Among organ-based clinical manifestations, only patients 
with ENT symptoms had a lower mean RDW than those with-
out (13.9% vs. 19.0%, p=0.001). However, there was no signifi-
cant difference in RDW between the presence and absence of 
PR3-ANCA (Fig. 1). 
Table 2. Correlation Coefficient between Red Blood Cell Distribution 
Width and Other Continuous Variables in Patients with ANCA-associat-
ed Vasculitis (n=150)
Variables
Correlation 
coefficient (R=β)
p value
Demographic data 
Age at diagnosis 0.135 0.099
Follow-up duration 0.103 0.211
BVAS, BVAS for GPA and FFS at diagnosis
BVAS or BVAS for GPA for AAV 0.060 0.469
Based on diagnosis 
BVAS of MPA 0.044 0.684
BVAS for GPA of GPA 0.461 0.008
BVAS of EGPA 0.204 0.272
FFS (1996) 0.131 0.111
FFS (2009) 0.156 0.057
Laboratory results at diagnosis
White blood cell 0.051 0.537
Haemoglobin -0.158 0.054
Platelet 0.005 0.949
Prothrombin time (INR) (n=116) 0.189 0.053
Fasting glucose 0.014 0.865
Blood urea nitrogen 0.166 0.042
Creatinine 0.119 0.148
Protein -0.261 0.001
Serum albumin -0.183 0.025
Alkaline phosphatase 0.155 0.059
Aspartate aminotransferase 0.121 0.142
Alanine aminotransferase 0.098 0.234
Total cholesterol -0.077 0.350
Acute reactants at diagnosis
ESR 0.028 0.738
CRP 0.046 0.581
ANCA, antineutrophil cytoplasmic antibody; BVAS, Birmingham vasculitis ac-
tivity score; GPA, granulomatosis with polyangiitis; MPA, microscopic poly-
angiitis; EGPA, eosinophilic granulomatosis with polyangiitis; FFS, five factor 
scores; INR, international normalised ratio; ESR, erythrocyte sedimentation 
rate; CRP, C-reactive protein. 
Table 3. Correlation Coefficients between Red Blood Cell Distribution 
Width and Other Continuous Variables in Patients with GPA (n=32)
Variables
Correlation 
coefficient (R=β)
p value
Demographic data 
Age at diagnosis 0.174 0.342
Follow-up duration -0.097 0.596
BVAS, BVAS for GPA and FFS at diagnosis
BVAS for GPA 0.461 0.008
FFS (1996) 0.455 0.009
FFS (2009) 0.553 0.001
Laboratory results at diagnosis
White blood cell -0.046 0.803
Haemoglobin 0.014 0.941
Platelet -0.085 0.643
Prothrombin time (INR) 0.141 0.576
Fasting glucose 0.138 0.450
Blood urea nitrogen 0.053 0.774
Creatinine 0.292 0.105
Protein -0.389 0.028
Serum albumin -0.054 0.770
Alkaline phosphatase 0.121 0.508
Aspartate aminotransferase 0.106 0.562
Alanine aminotransferase -0.005 0.980
Total cholesterol -0.156 0.403
Acute reactants at diagnosis
ESR 0.128 0.484
CRP 0.067 0.717
GPA, granulomatosis with polyangiitis; BVAS, Birmingham vasculitis activity 
score; FFS, five factor scores; INR, international normalised ratio; ESR, eryth-
rocyte sedimentation rate; CRP, C-reactive protein. 
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The optimal cut-off of RDW to predict severe GPA at 
diagnosis
In this study, we defined severe GPA as BVAS for GPA ≥7. We 
divided GPA patients into severe and not severe GPA groups 
according to it. Eleven patients were in the severe GPA group 
and 21 patients were in the not severe GPA group. The mean 
RDW of severe GPA group was higher than that of not severe 
GPA group (16.8% and 13.8%, p=0.032). We calculated the op-
timal cut-off of RDW to predict severe GPA, and we discov-
ered that 15.4% was a strong predictor of severe GPA (AUROC 
0.732, 95% CI 0.527–0.936, p=0.034; sensitivity 54.5% and speci-
ficity 95.2%) (Supplementary Fig. 1A, only online). We also re-
classified the 32 GPA patients into two groups according to the 
optimal cut-off of RDW. Severe GPA (BVAS for GPA ≥7) was 
identified more frequently in patients having RDW ≥15.4% 
than those having RDW <15.4% (85.7% vs. 20.0%, p=0.001) 
(Supplementary Fig. 1B, only online). Furthermore, patients 
with RDW ≥15.4% had a significant higher risk of severe GPA 
than those without (RR 24.0, 95% CI 2.329–247.368). 
Predictors of prognosis during the follow-up duration  
Since BVAS for GPA, FFS (1996), FFS (2009), and ENT symp-
toms were significantly related to RDW, we divided GPA pa-
tients into groups according to BVAS ≥7 or <7, FFS (1996) ≥1 
or <1, FFS (2009) ≥1 or <1, RDW ≥15.4% or <15.4%, and the 
presence or absence of ENT manifestation based on our pre-
vious studies.16-18 We used univariate and multivariate Cox haz-
ards models to analyse the potential for predicting the prog-
nosis of GPA in disease processes. In terms of relapse of GPA, 
there was no statistically significant predictor among them. In 
terms of refractory disease of GPA, univariate analysis showed 
that BVAS ≥7, FFS (1996) ≥1 and FFS (2009) ≥1 at diagnosis 
were not predicted thereof. Meanwhile, patients having RDW 
≥15.4% and having no ENT symptoms at diagnosis exhibited 
a significantly increased risk of refractory GPA than those hav-
ing RDW <15.4% and ENT manifestation (RR 19.527, 95% CI 
2.271–167.905, and RR 0.177, 95% CI 0.035–0.890, respective-
ly). Multivariate Cox hazards analysis showed RDW ≥15.4% to 
be the only significant predictor of refractory GPA (RR 17.573, 
95% CI 1.701–181.586). There were significant differences in 
Table 4. Univariate and Multivariate Linear Regression Analyses of BVAS for GPA in Patients with GPA (n=32)
Variables
Univariate analysis Multivariate analysis
Regression 
coefficient 
(Crude B)
Correlation 
coefficient 
(R=β)
p value
Standardized
β*
95% 
confidential interval
p value
Demographic data 
Age at diagnosis -0.038 -0.174 0.340
Follow-up duration -0.012 -0.140 0.446
FFSs at diagnosis*
FFS (1996) 2.871 0.734 <0.001
FFS (2009) 1.127 0.354 0.047
RDW at diagnosis 0.367 0.461 0.008 0.393  0.041–0.584 0.025
Laboratory results at diagnosis
White blood cell 0.000 0.153 0.404
Haemoglobin 0.227 0.114 0.533
Platelet -0.003 -0.151 0.411
Prothrombin time (INR) (n=59) 3.453 0.154 0.624
Fasting glucose 0.025 0.302 0.093
Blood urea nitrogen 0.038 0.258 0.154
Creatinine 0.655 0.349 0.049 0.235 -0.199–1.078 0.170
Protein -1.189 -0.310 0.084
Serum albumin -1.185 -0.288 0.110
Alkaline phosphatase 0.006 0.240 0.186
Aspartate aminotransferase 0.029 0.231 0.203
Alanine aminotransferase 0.023 0.109 0.601
Total cholesterol -0.019 -0.309 0.091
Acute reactants at diagnosis
ESR 0.006 0.071 0.698
CRP 0.014 0.327 0.067
RDW, red blood cell distribution width; GPA, granulomatosis with polyangiitis; BVAS, Birmingham vasculitis activity score; FFS, five factor scores; INR, interna-
tional normalised ratio; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein. 
*We did not include FFS (1996) and FFS (2009) in multivariate linear regression analysis due to overlapped items between BVAS and FFS. 
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cumulative refractory disease free survival rates according to 
RDW ≥15.4% (p=0.007) and the absence of ENT manifestation 
(p=0.036) (Fig. 2). 
DISCUSSION
In this study, we first demonstrated that RDW can predict vas-
culitis activity in patients with GPA. RDW was significantly 
correlated with BVAS for GPA in GPA patients, and further-
more, RDW was the only independent predictor of BVAS for 
GPA among other variables in multivariate linear regression 
analysis. We also found that an increase in RDW was associat-
ed with the absence of ENT symptoms, but not PR3-ANCA. In 
addition, we discovered that 15.4% of RDW was a strong pre-
dictor of severe GPA. Moreover, we found that patients having 
RDW ≥15.4% and having no ENT manifestation at diagnosis 
faced a significantly higher risk of refractory disease of GPA 
than those without these features during follow-up of at least 
more than 12 weeks. RDW ≥15.4% was the only significant 
predictor of refractory GPA in multivariate analysis. Taken to-
gether, we concluded that RDW can predict vasculitis activity 
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of GPA and that RDW ≥15.4% at diagnosis not only increases 
the risk of severe GPA, but also predicts refractory diseases 
during follow-up. 
RDW is clinically used to differentiate between different 
types of anaemia, particularly iron deficiency anaemia and 
anaemia of chronic disease.11 However, in this study, RDW 
was not significantly associated with haemoglobin. In order to 
reduce the effect of anaemia on the association of RDW with 
vasculitis activity of GPA, we excluded 5 patients with anae-
mia (haemoglobin<12.0 g/dL) and reanalysed the potential of 
RDW to predict vasculitis activity in 27 patients with GPA. 
RDW was positively correlated with BVAS for GPA, FFS (1996) 
and FFS (2009) and negatively correlated with protein (p<0.05 
for all). However, RDW was not correlated with haemoglobin, 
ESR or CRP (Supplementary Table 1, only online). Univariate 
linear regression analysis showed BVAS for GPA to be signifi-
cantly associated with RDW (r=0.470, p=0.013) and serum al-
bumin (r=-0.388, p=0.045). Multivariate linear regression anal-
ysis revealed that RDW was the only independent predictor of 
BVAS for GPA (β=0.449, 95% CI 0.083–0.598, p=0.012) (Supple-
mentary Table 2, only online). The highest quartile of BVAS for 
GPA for severe GPA was a score of 7 or greater, and therewith, 
the optimal cut-off of RDW to predict severe GPA was 13.7% 
(AUROC 0.735, 95% CI 0.522–0.946, p=0.045; sensitivity 80.0% 
and specificity 70.6%) (Supplementary Fig. 1C, only online). 
Patients with RDW ≥13.7% also had a significant higher risk of 
severe GPA than those without (RR 9.6, 95% CI 1.283–62.162) 
(Supplementary Fig. 1D, only online). However, RDW ≥13.7% 
could not predict refractory disease in GPA patients without 
anaemia. Taken together, we concluded that independent of 
concurrent anaemia, RDW can predict vasculitis activity of 
GPA at the same time, but not refractory disease during follow-
up. Thus, in clinical settings, we suggest RDW ≥15.4% as a pre-
dictor of severe GPA and refractory disease development dur-
ing the follow-up duration in GPA patients without anaemia. 
In general, pro-inflammatory cytokines may be involved in 
the development of anaemia in a variety of diseases.23 In the 
early stage of GPA, large amounts of pro-inflammatory cyto-
kines produced by macrophages and T cells, such as tumour 
necrosis factor-α and interleukin-6, stimulate and prime neu-
trophils, and primed neutrophils are subsequently activated by 
PR3-ANCA. Activated neutrophils migrate into adjacent tissues 
and predominantly induce inflammation primarily through 
innate immune responses. However, in the sclerotic progres-
sion stage of GPA, macrophages and autoreactive lympho-
cytes rather than activated neutrophils participate in the for-
mation of pathergic necrosis and necrotising granulomatosis.24 
Therefore, the effect of the pathophysiology of GPA on the de-
velopment of anaemia at the time of diagnosis of GPA might 
be theoretically reduced compared to the early stage of GPA. 
The lack of correlation between RDW and ESR or CRP in this 
study might support this assumption. Furthermore, this explain 
about the discrepancy between this study and previous stud-
ies with relatively urgent diseases with much inflammatory 
burden including acute myocardial infarction, sepsis, and can-
cer.25-27 We hypothesised that large amounts of pro-inflamma-
tory cytokines may induce anaemia and increase RDW, along 
with ESR and CRP, in rapidly progressive inflammatory dis-
eases, while small amounts of pro-inflammatory cytokines may 
induce subclinical anaemia and increase RDW, but not ESR 
or CRP in slowly progressive diseases like GPA. This hypothe-
sis may be supported by our findings among which RDW was 
significantly associated with BVAS for GPA after excluding 
anaemic patients and RDW, instead of ESR and CRP, at diag-
nosis could predict refractory GPA during follow-up.
Since PR3-ANCA is known to play the most important role in 
the pathogenesis of GPA, it was thought that PR3-ANCA should 
be related to vasculitis activity of GPA. However, in this study, 
PR3-ANCA was not correlated with BVAS for GPA, and further-
more, it could not predict refractory disease during the follow-
up duration. Although the significance of PR3-ANCA positivi-
ty in the rate of relapse or refractory disease of GPA has been 
debated, PR3-ANCA seems to be closely associated with poor 
prognosis in the disease course.28-30 However, our study could 
not clarify the contribution of PR3-ANCA to poor outcome of 
GPA. Ethnic differences may affect differences in factors that 
affect the poor prognosis of GPA.31 
In addition to RDW, RDW to platelet ratio has been recently 
reported to be associated with severity in several conditions.32,33 
We investigated the association between RDW to platelet ratio 
and vasculitis activity of GPA by univariable linear regression 
analysis. RDW to platelet ratio exhibited a tendency to be cor-
related with BVAS of GPA, but it was not statistically signifi-
cant (r=0.325, 95% CI -3.230–78.145, p=0.070).
The strengths of our study are as follows: first, we first dem-
onstrated that RDW is the only independent predictor of BVAS 
for GPA. Second, we first suggested the optimal cut-off of RDW 
to predict severe GPA (the highest quartile of BVAS for GPA) 
and demonstrated that the optimal cut-off of RDW at diagno-
sis reflects an increased risk of refractory disease in GPA pa-
tients during follow-up. Our study also had several limitations. 
First, the optimal cut-off of RDW to predict severe GPA was 
changed according to the presence of anaemia, which might 
reduce the clinical usefulness of RDW in clinical settings. Sec-
ond, serial measurements of RDW and BVAS for GPA were not 
available. Third, this study has limitations as a retrospective 
study, with a small number of patients with GPA. If future stud-
ies can prospectively enrol a larger number of GPA patients 
and serially measure RDW and BVAS for GPA, they may reveal 
a dynamic correlation between RDW and vasculitis activity of 
GPA, and propose more reliable factors with which to predict 
the prognosis of GPA. 
In conclusion, RDW may be an independent predictor of 
BVAS for GPA regardless of anaemia, and predict refractory 
disease of GPA during follow-up in patients without anaemia. 
Therefore, we suggest that general physicians can use RDW of 
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more than 15.4% as a predictor of high vascular activity and 
poor prognosis in patients with GPA.
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